Kaken Pharmaceutical Co - 股票

Kaken Pharmaceutical Co 股本 2024

Kaken Pharmaceutical Co 股本

143.76 亿 JPY

股票代码

4521.T

ISIN

JP3207000005

在2024年,Kaken Pharmaceutical Co的股本为143.76 亿 JPY,比上一年的137.75 亿 JPY资本增长了4.36%

Kaken Pharmaceutical Co Aktienanalyse

Kaken Pharmaceutical Co在做什么?

Kaken Pharmaceutical Co Ltd is a Japanese pharmaceutical company based in Tokyo. The company was founded in 1949 and has since grown continuously to establish itself as a flagship of the Japanese pharmaceutical industry. The company specializes in the production and sale of prescription and over-the-counter drugs. However, it has also heavily focused on research and development of new medications to expand its market share. Kaken Pharmaceutical's business model is to develop and manufacture high-quality products to ensure they meet the needs and requirements of customers. This includes a wide range of medications, ranging from pain relievers and antiallergics to cosmetic products. The company categorizes its products into five different categories: dermatology, pediatrics, oncology, gastroenterology, and orthopedics. Each of these categories specializes in treating and preventing various diseases, conditions, and complaints, offering a wide range of products. Dermatology is one of the key divisions of Kaken Pharmaceutical. The company offers medications for treating skin conditions such as psoriasis, eczema, dermatitis, and acne. One of its most well-known products is the anti-acne medication Isotretinoin. It works by reducing sebum production, thus reducing inflammation and pore blockage. Kaken Pharmaceutical's pediatrics products focus on treating children. Syrups and drops for symptom relief of colds, coughs, fevers, and diarrhea are among the products offered. In this category, Kaken Pharmaceutical also provides medications for treating children with ADHD. Oncology medications are offered by Kaken Pharmaceutical under the name "Kaken Pharma." These products are intended for the treatment of cancer diseases such as lung, breast, and stomach cancer. The company is constantly striving to improve its research and development to make cancer treatment more effective and efficient. The gastroenterology category focuses on treating digestive disorders such as heartburn, reflux, and gastric ulcers. Kaken Pharmaceutical has introduced several products, including drugs that inhibit stomach acid, which are offered in the form of tablets and granules. Orthopedic medications from Kaken Pharmaceutical are used to treat pain and inflammation of the skeletal system, such as relieving joint pain, arthritis, and osteoporosis. The most well-known product is the pain reliever Ibuprofen, which is available for both oral and topical use. In conclusion, Kaken Pharmaceutical Co Ltd is a company committed to meeting the medical and cosmetic needs of customers. Each product is carefully developed and manufactured to ensure the highest quality and effectiveness. With its wide range of products and research efforts, the company is an important player in the global pharmaceutical market. Kaken Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

股本的详细信息

Kaken Pharmaceutical Co的股本分析

Kaken Pharmaceutical Co的股本代表了公司的所有者权益,是总资产与总负债之间的差额。它反映了在所有债务都得到偿还之后,股东对公司资产的剩余权益。理解Kaken Pharmaceutical Co的股本对评估其财务健康,稳定性以及对股东的价值至关重要。

年对年比较

评估Kaken Pharmaceutical Co连续几年的股本,可以提供有关公司的增长,盈利能力以及资本结构的观点。股本的增长表明净资产和财务健康的改善,而股本的减少可能表明债务的增加或运营上的挑战。

对投资的影响

Kaken Pharmaceutical Co的股本对投资人来说是一个关键的元素,它影响了公司的杠杆,风险档案以及股本回报率(ROE)。较高的股本水平通常预示着较低的风险和增加的财务稳定性,使得公司可能成为有吸引力的投资机会。

解读股本波动

Kaken Pharmaceutical Co的股本波动可能源于各种因素,包括净利润的变动,分红,以及发行或回购股票。投资人分析这些变化,以评估公司的财务表现,运营效率和战略财务管理。

关于Kaken Pharmaceutical Co股票的常见问题

Kaken Pharmaceutical Co今年的股本是多少?

Kaken Pharmaceutical Co今年的股本为143.76 亿 JPY。

Kaken Pharmaceutical Co的股本与去年相比高了多少?

Kaken Pharmaceutical Co的股本与去年相比,4.36上涨。

Kaken Pharmaceutical Co的投资者高额的股本会产生什么影响?

对于Kaken Pharmaceutical Co的投资者来说,高额的股本是有利的,因为它是公司财务稳定性的指标,展示了公司应对风险和挑战的能力。

Kaken Pharmaceutical Co的投资者低资本充足率会有什么影响?

对于Kaken Pharmaceutical Co的投资者来说,较低的自有资本可能构成风险,因为这会使公司处于较弱的财务地位,并可能影响其应对风险和挑战的能力。

Kaken Pharmaceutical Co的股本增加对公司有什么影响?

增加Kaken Pharmaceutical Co的股本可以强化公司的财务状况,提高其未来投资的能力。

Kaken Pharmaceutical Co的股本减少会如何影响公司?

Kaken Pharmaceutical Co的股本减少可能会影响公司的财务状况,并导致对债务资金的依赖度增加。

什么因素会影响Kaken Pharmaceutical Co的股本?

一些可能影响Kaken Pharmaceutical Co股本的因素包括利润,股息支付,增资和收购。

为什么Kaken Pharmaceutical Co的股本对投资者如此重要?

Kaken Pharmaceutical Co的股本对投资者非常重要,因为它是公司财务实力的指标,也可能是该公司有能力履行其财务义务的迹象。

Kaken Pharmaceutical Co可以采取哪些战略措施来改变自己的股本?

为了改变自身的股本,Kaken Pharmaceutical Co可以采取包括提高利润,实施增资,减少开支和收购企业等多种措施。对公司来说,彻底检查其财务状况以确定最佳的策略性措施来改变其股本的情况非常重要。

Kaken Pharmaceutical Co支付多少股息?

在过去的12个月中,Kaken Pharmaceutical Co支付了150 JPY 的股息。这相当于大约3.96 %的股息收益率。在未来的12个月内,Kaken Pharmaceutical Co预计将支付155.09 JPY的股息。

Kaken Pharmaceutical Co的股息收益率有多高?

Kaken Pharmaceutical Co当前的股息收益率为3.96 %。

Kaken Pharmaceutical Co什么时候支付股息?

Kaken Pharmaceutical Co按季度支付股息。这些股息将在, , , 月份分发。

Kaken Pharmaceutical Co的股息有多安全?

Kaken Pharmaceutical Co 在过去23年里每年都支付了股息。

Kaken Pharmaceutical Co的股息有多高?

预计未来12个月的股息将达到155.09 JPY。这相当于4.09 %的股息收益率。

Kaken Pharmaceutical Co位于哪个行业?

Kaken Pharmaceutical Co 被分配到“健康”板块。

Wann musste ich die Aktien von Kaken Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

要获得Kaken Pharmaceutical Co在支付的75 JPY的最后一笔股息,你必须在的除息日之前持有该股票于你的账户中。

Kaken Pharmaceutical Co最后一次支付股息是什么时候?

上一次股息发放日期为。

Kaken Pharmaceutical Co在2023年的股息是多少?

在2023年,Kaken Pharmaceutical Co 分配了150 JPY作为股息。

Kaken Pharmaceutical Co 的股息是以哪种货币支付的?

Kaken Pharmaceutical Co的股息将以JPY的形式分配。

股票储蓄计划为投资者提供了一种吸引人的方法,可以长期累积财富。主要优势之一是所谓的成本平均效应:通过定期投入固定金额于股票或股票基金,当价格低时自动买入更多份额,价格高时买入较少,这可能随着时间带来更优惠的平均每份成本。此外,股票储蓄计划还允许小额投资者接触到高价股票,因为他们可以用很小的金额参与其中。定期投资也促进了一种纪律投资策略,并有助于避免情绪化的决策,如冲动买卖。除此之外,投资者还能从股票的潜在增值以及可以再投资的股息分红中获益,这增强了复利效应,从而增加了投资资本的增长。

Andere Kennzahlen von Kaken Pharmaceutical Co

我们对Kaken Pharmaceutical Co 营业额股票的股票分析包括重要的财务指标,如收入、利润、市盈率、市销率、息税折旧摊销前利润,以及有关股息的信息。此外,我们还研究了诸如股票、市值、债务、股东权益和Kaken Pharmaceutical Co 营业额的负债等方面。如果您在寻找关于这些主题的更详细信息,我们在子页面上提供了详细的分析: